Clinical trial · Interventional
ANET Electrosurgery Applicator Pilot Evaluation Study
NCT03400748CI-TRIAL-00075645terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): business reason
Summary
Brief summary (as posted)
Evaluate the preliminary safety and performance of the Electrosurgery Applicator (ANET device) during and after bronchoscopic ablation of a target pulmonary nodule/tumor.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer Metastatic | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RF Ablation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- RF Ablation
- description
- Single-arm study where subjects receive RF ablation prior to a scheduled surgical resection.
- interventionNames
- Device: RF Ablation
Primary outcomes (1)
- measure
- ANET Related Peri-procedural Adverse Events
- timeFrame
- Day 0
- description
- The incidence of reported adverse events and serious adverse events related to the ANET device or procedure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subject with Stage I or Stage II primary lung cancer or metastatic lung tumor 2. Pathological proof of target nodule/tumor type and malignancy 3. Target nodule/tumor which can be accessed via EBUS bronchoscopy 4. Resection/surgical candidate 5. Participants must be at least 18 years old and able to provide consent Exclusion criteria: 1. Subjects in whom flexible bronchoscopy is contraindicated 2. Target nodule \< 1.0 cm 3. Prior radiation or neo adjuvant chemotherapy of the target nodule/tumor 4. Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives 5. Pacemaker, implantable cardioverter, or other electronic implantable device
References
Publications (0)
Data not yet available
No reference posted for this study.